Three patients (all melanoma) had plasma collection immediately after coming off BRAF or MEK targeted therapy and 1 patient (appendiceal cancer) had plasma collection right after being taken off standard chemotherapy without evidence of disease progression. This evidence concerns the gene MAP2K7 and melanoma.